These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

454 related articles for article (PubMed ID: 35258371)

  • 41. Transarterial Radioembolization Following Chemoembolization for Unresectable Hepatocellular Carcinoma: Response Based on Apparent Diffusion Coefficient Change is an Independent Predictor for Survival.
    Klompenhouwer EG; Dresen RC; Verslype C; Laenen A; Bonne L; Vandecaveye V; Maleux G
    Cardiovasc Intervent Radiol; 2018 Nov; 41(11):1716-1726. PubMed ID: 29872894
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Transarterial chemoembolization plus lenvatinib versus transarterial chemoembolization plus sorafenib as first-line treatment for hepatocellular carcinoma with portal vein tumor thrombus: A prospective randomized study.
    Ding X; Sun W; Li W; Shen Y; Guo X; Teng Y; Liu X; Zheng L; Li W; Chen J
    Cancer; 2021 Oct; 127(20):3782-3793. PubMed ID: 34237154
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Conventional versus Doxorubicin-Eluting Beads Transarterial Chemoembolization for Unresectable Hepatocellular Carcinoma: a Tertiary Medical Centre Experience in Malaysia.
    Rahman FA; Naidu J; Ngiu CS; Yaakob Y; Mohamed Z; Othman H; Jarmin R; Elias MH; Hamid NA; Mokhtar NM; Ali RR
    Asian Pac J Cancer Prev; 2016; 17(8):4037-41. PubMed ID: 27644658
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Transarterial Chemoembolization With Drug-Eluting Beads Versus Stereotactic Body Radiation Therapy for Hepatocellular Carcinoma: Outcomes From a Multicenter, Randomized, Phase 2 Trial (the TRENDY Trial).
    Méndez Romero A; van der Holt B; Willemssen FEJA; de Man RA; Heijmen BJM; Habraken S; Westerveld H; van Delden OM; Klümpen HJ; Tjwa ETTL; Braam PM; Jenniskens SFM; Vanwolleghem T; Weytjens R; d'Archambeau O; de Vos-Geelen J; Buijsen J; van der Leij C; den Toom W; Sprengers D; IJzermans JNM; Moelker A
    Int J Radiat Oncol Biol Phys; 2023 Sep; 117(1):45-52. PubMed ID: 37037359
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [Comparison of doxorubicin-eluting bead transarterial chemoembolization (DEB-TACE) with conventional transarterial chemoembolization (TACE) for the treatment of hepatocellular carcinoma].
    Ferrer Puchol MD; la Parra C; Esteban E; Vaño M; Forment M; Vera A; Cosín O
    Radiologia; 2011; 53(3):246-53. PubMed ID: 21295802
    [TBL] [Abstract][Full Text] [Related]  

  • 46. TACE versus TARE for patients with hepatocellular carcinoma: Overall and individual patient level meta analysis.
    Brown AM; Kassab I; Massani M; Townsend W; Singal AG; Soydal C; Moreno-Luna L; Roberts LR; Chen VL; Parikh ND
    Cancer Med; 2023 Feb; 12(3):2590-2599. PubMed ID: 35943116
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Treatment efficacy and safety of drug-eluting beads transarterial chemoembolization versus conventional transarterial chemoembolization in hepatocellular carcinoma patients with arterioportal fistula.
    Cai L; Li H; Guo J; Zhao W; Duan Y; Hou X; Cheng L; Du H; Shao X; Diao Z; Hao Y; Zheng X; Li C; Li W
    Cancer Biol Ther; 2022 Dec; 23(1):89-95. PubMed ID: 35230928
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Idarubicin versus epirubicin in drug-eluting beads-transarterial chemoembolization for treating hepatocellular carcinoma: A real-world retrospective study.
    Zhao C; Yan H; Xiang Z; Wang H; Li M; Huang M
    Invest New Drugs; 2023 Aug; 41(4):617-626. PubMed ID: 37434023
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Survival benefit with intraarterial techniques in hepatocellular carcinoma].
    Sangro B
    Gastroenterol Hepatol; 2014 Jul; 37 Suppl 2():95-101. PubMed ID: 25087719
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Survival in unresectable AJCC stage I and II HCC and the effect of DEB-TACE: SEER versus tertiary cancer center cohort study.
    Xing M; Kokabi N; Prajapati HJ; Close O; Ludwig JM; Kim HS
    J Comp Eff Res; 2016 Mar; 5(2):141-54. PubMed ID: 26946950
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Super-selective transarterial chemoembolization of hepatocellular carcinoma with doxorubicin-eluting beads sized 40-75 microns: assessment of efficacy and safety.
    Ballı HT; Aikimbaev K
    Diagn Interv Radiol; 2020 Sep; 26(5):482-487. PubMed ID: 32815520
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Prognostic factors for survival in patients with unresectable hepatocellular carcinoma undergoing chemoembolization with doxorubicin drug-eluting beads: a preliminary study.
    Dhanasekaran R; Kooby DA; Staley CA; Kauh JS; Khanna V; Kim HS
    HPB (Oxford); 2010 Apr; 12(3):174-80. PubMed ID: 20590884
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The impact of drug-eluting bead (vs. conventional) transarterial chemoembolization on hepatic fibrosis in treating intermediate or advanced hepatocellular carcinoma.
    Li H; Liang C; Kuang D; Huang G; Zhang M; Chen P; Zheng Q; Xu W; Ren J; Han X; Duan X
    Cancer Biol Ther; 2023 Dec; 24(1):2166335. PubMed ID: 36751709
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Objective Tumor Response of Hepatocellular Carcinoma Obtained by Transarterial Radioembolization with Iodine-131-Lipiodol Versus Transarterial Chemoembolization for Patients with and without Portal Venous Thrombosis: A Controlled Interventional Trial.
    Oliveira Ribeiro MC; Moda KA; Alvarez M; Koga KH; Moriguchi SM; Carvalho FC; Pinheiro RSN; Qi X; Romeiro FG
    Acad Radiol; 2024 May; 31(5):1839-1848. PubMed ID: 38016824
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Chemoembolization Versus Radioembolization for Neuroendocrine Liver Metastases: A Meta-analysis Comparing Clinical Outcomes.
    Ngo L; Elnahla A; Attia AS; Hussein M; Toraih EA; Kandil E; Killackey M
    Ann Surg Oncol; 2021 Apr; 28(4):1950-1958. PubMed ID: 33393019
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Clinical outcomes of doxorubicin-eluting CalliSpheres® beads-transarterial chemoembolization for unresectable or recurrent esophageal carcinoma.
    Bi Y; Shi X; Ren J; Yi M; Han X; Song M
    BMC Gastroenterol; 2021 May; 21(1):231. PubMed ID: 34020608
    [TBL] [Abstract][Full Text] [Related]  

  • 57. A comparison between drug-eluting bead-transarterial chemoembolization and conventional transarterial chemoembolization in patients with hepatocellular carcinoma: A meta-analysis of six randomized controlled trials.
    Wang H; Cao C; Wei X; Shen K; Shu Y; Wan X; Sun J; Ren X; Dong Y; Liu Y; Zhai B
    J Cancer Res Ther; 2020; 16(2):243-249. PubMed ID: 32474508
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Five-year outcome of conventional and drug-eluting transcatheter arterial chemoembolization in patients with hepatocellular carcinoma.
    Liu YS; Lin CY; Chuang MT; Lin CY; Tsai YS; Wang CK; Ou MC
    BMC Gastroenterol; 2018 Aug; 18(1):124. PubMed ID: 30075752
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Comparison of Response and Outcomes of Drug-eluting Bead Chemoembolization (DEB-TACE)
    Mokkarala M; Noda C; Malone C; Ramaswamy R; Akinwande O
    Anticancer Res; 2019 Jun; 39(6):3071-3077. PubMed ID: 31177151
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Prospective randomized comparison of chemoembolization with doxorubicin-eluting beads and bland embolization with BeadBlock for hepatocellular carcinoma.
    Malagari K; Pomoni M; Kelekis A; Pomoni A; Dourakis S; Spyridopoulos T; Moschouris H; Emmanouil E; Rizos S; Kelekis D
    Cardiovasc Intervent Radiol; 2010 Jun; 33(3):541-51. PubMed ID: 19937027
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 23.